SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Anxu

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved in China (NMPA); Phase III ongoing for cGVHD
Time to market
Already marketed in China. Timeline for US/EU regulatory filings is not yet disclosed; Sanofi is still in early-stage global development.
Why 3/10
No hard dated catalyst (PDUFA, pivotal readout) is scheduled in the next ~12 months. The drug is already approved and commercializing in China, and Sanofi is a large diversified pharma for which this is a small pipeline asset. The Phase III cGVHD trial is still recruiting with no disclosed readout date.
Actionable Insight NEUTRAL

Watch for Sanofi's progress advancing rovadicitinib into US/EU clinical trials and any Phase III cGVHD data readouts, which would be the next meaningful catalysts. The drug is already generating commercial revenue in China, but for Sanofi's stock, this is a minor contributor relative to Dupixent and other core franchises.

Price Chart

Loading chart...

Executive Summary

Anxu (rovadicitinib) is a first-in-class oral JAK/ROCK dual inhibitor approved in China since February 2026 for myelofibrosis. Sanofi licensed global rights in March 2026 for $135M upfront and up to $1.53B total. The drug launched in China in Q2 2026 with Sanofi reporting initial sales in Q3 2026. Sanofi's core interest is in chronic graft-versus-host disease (cGVHD), where a Phase III trial is ongoing in China. No US or EU regulatory filing has occurred yet. For a company the size of Sanofi, this is a small pipeline addition with no imminent binary catalyst.

How It Works

Anxu is a pill that blocks two cellular pathways (JAK-STAT and ROCK) involved in inflammation and fibrosis. By inhibiting both pathways simultaneously, it aims to reduce abnormal cell growth and inflammatory signaling in bone marrow cancers like myelofibrosis and in immune-driven conditions like chronic graft-versus-host disease.

Trial Status

Approved in China for first-line myelofibrosis (February 2026). A Phase III trial for moderate-to-severe chronic graft-versus-host disease (cGVHD) in third-line and beyond is recruiting in China (NCT06682169). Phase Ib/IIa data for cGVHD published in Blood showed a 59.1% overall response rate and corticosteroid dose reduction in 88.6% of patients.

The Two-Sided Case

▲ Bull Case4
First-in-class dual JAK/ROCK inhibitor with a differentiated mechanism that could address both inflammatory and fibrotic components of disease
Already approved and generating revenue in China, de-risking the mechanism
Strong Phase Ib/IIa cGVHD data published in Blood showing 59.1% response rate and steroid-sparing effect, supporting a large addressable market
Sanofi's existing Rezurock franchise in cGVHD provides commercial infrastructure and synergies
▼ Bear Case5
For Sanofi, a $53B market-cap company, this is a small pipeline addition with no near-term impact on the stock
No US or EU regulatory filing has occurred; global development timeline is uncertain and likely years away
The myelofibrosis market is competitive with approved JAK inhibitors like ruxolitinib, fedratinib, and pacritinib
Phase III cGVHD trial is still recruiting with no completion date; clinical and regulatory risk remains
Sanofi's stock has seen multiple analyst downgrades in late 2025/early 2026 and mixed institutional sentiment

Upcoming Catalysts

  • Phase III cGVHD trial data readout (NCT06682169, recruiting as of August 2026, no estimated completion date published)
  • Potential US IND filing and early-phase trial initiation by Sanofi
  • Quarterly China sales trajectory updates from Sanofi earnings

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 10

Hover a chip for the title
1 fiercepharma.com2 en.sbpgroup.com3 pmc.ncbi.nlm.nih.gov4 pharmaceutical-technology.com5 stockanalysis.com6 clinicaltrials.gov7 ashpublications.org8 sanofi.com9 bioxconomy.com10 reuters.com